Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsors and Collaborators: |
FDA Office of Orphan Products Development Georgetown University |
---|---|
Information provided by: | FDA Office of Orphan Products Development |
ClinicalTrials.gov Identifier: | NCT00004495 |
OBJECTIVES: I. Compare the efficacy of two doses of folic acid in normalizing plasma total homocysteine concentration in patients with end stage renal disease receiving regular hemodialysis therapy resulting in hyperhomocysteinemia.
II. Determine the requirement of co-supplementation with extra pyridoxine (vitamin B6) and cyanocobalamin (vitamin B12) daily in these patients.
III. Assess the safety and tolerability of this therapy in these patients.
Condition | Intervention |
---|---|
End Stage Renal Disease Hyperhomocysteinemia |
Drug: cyanocobalamin Drug: folic acid Drug: pyridoxine |
Study Type: | Interventional |
Study Design: | Treatment, Efficacy Study |
Estimated Enrollment: | 84 |
Study Start Date: | June 1999 |
PROTOCOL OUTLINE: This is a randomized, placebo controlled study. Patients are stratified according to prestudy homocysteine levels (above or below average). Patients are randomized to receive placebo or one of two doses of oral folic acid, with or without pyridoxine and cyanocobalamin.
Arm I: Patients receive oral placebo daily. Arm II: Patients receive oral pyridoxine, cyanocobalamin, and oral placebo daily.
Arm III: Patients receive oral pyridoxine, cyanocobalamin, and folic acid daily.
Arm IV: Patients receive oral pyridoxine and cyanocobalamin plus a higher dose of folic acid daily.
Arm V: Patients receive oral placebo and oral folic acid daily. Arm VI: Patients receive oral placebo and higher dose folic acid daily. Treatment continues for 8 weeks.
Ages Eligible for Study: | 21 Years to 89 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
PROTOCOL ENTRY CRITERIA:
--Disease Characteristics--
--Prior/Concurrent Therapy--
--Patient Characteristics--
United States, District of Columbia | |
Georgetown University Medical Center | Recruiting |
Washington, District of Columbia, United States, 20007 | |
Contact: Christopher S. Wilcox 202-687-8539 |
Study Chair: | Christopher S. Wilcox | Georgetown University |
Study ID Numbers: | 199/14276, GUMC-FDR001544 |
Study First Received: | October 18, 1999 |
Last Updated: | June 23, 2005 |
ClinicalTrials.gov Identifier: | NCT00004495 |
Health Authority: | United States: Federal Government |
cardiovascular and respiratory diseases end stage renal disease hyperhomocysteinemia rare disease renal and genitourinary disorders |
Renal Insufficiency Metabolic Diseases Hyperhomocysteinemia Amino Acid Metabolism, Inborn Errors Hydroxocobalamin Respiration Disorders Kidney Failure, Chronic Rare Diseases Vitamin B 12 Vitamin B 6 |
Folic Acid Metabolism, Inborn Errors Inborn amino acid metabolism disorder Urologic Diseases Genetic Diseases, Inborn Renal Insufficiency, Chronic Pyridoxine Kidney Diseases Metabolic disorder Kidney Failure |
Vitamin B Complex Hematinics Therapeutic Uses Growth Substances Vitamins |
Hematologic Agents Physiological Effects of Drugs Micronutrients Pharmacologic Actions |